Cri-du-chat syndrome is a rare genetic condition characterized by the absence of genetic material on the small arm of chromosomes. This missing portion on specific chromosomes has a significant impact on a child’s ability to communicate. This syndrome affects approximately one in every 50,000 infants. Cri-du-chat syndrome is also known as 5p syndrome or the cat cry syndrome. In newborn children, a cat-like cry is the most significant clinical sign for identifying this disorder. Children who have Cri-du-chat syndrome are more likely to seek the assistance of their parents, therapists, and educational professionals. This syndrome is usually associated with babies with a small head, folds of skin across eyelids, low birth weight, small chin, cat-like cry, palate abnormalities, and ear malformation.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies, together with governments globally, are working to address the COVID-19 outbreak from supporting the development of vaccines to planning the medicine supply chain challenges.

Currently, around 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs, including Hydroxychloroquine has witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of the COVID-19 management drugs as many developed countries are facing shortages. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the rise in demand for vaccine and treatment drugs for COVID-19. This in turn, is expected to have a significant impact on the global Cri-du-chat syndrome treatment market.

Top Impacting Factors

• Emerging research and advancements for developing efficient and cost-effective treatments and introduction of novel drugs are expected to drive significant growth in the global Cri-du-chat syndrome treatment market.
• Furthermore, the increased prevalence of Cri-du-chat syndrome treatment-related cases is a major driving force for market expansion in the forecast years.
• The increase in demand for therapies such as developmental therapy and behavioral therapy is also propelling market expansion.
• The increase in demand for diagnostics employing the fluorescent in situ hybridization (FISH) technology and the Genetic Testing Registry (GTR) is likely to drive market expansion in the coming years.
• In addition, supportive government initiatives, the rise in healthcare expenditure, and increased awareness of the Cry Do Chat condition are likely to boost market expansion during the forecast period.
• However, pre-linked genetic abnormalities may hinder the growth of the Cri-du-chat syndrome treatment market during the forecast period.

Market Trends

New Product Launches to Flourish Cri-du-chat syndrome Treatment Market 

In January 2020, Quest Diagnostics acquired Blueprint Genetics to enhance its expertise in genetic disorders and rare diseases. 

In June 2018, Centogene launched its diagnostic laboratory in Cambridge, Massachusetts.

In February 2020, Dante Labs launched an initiative to offer WGS to patients with rare diseases for $299. The service included WGS 30X on Novaseq6000 technology, data interpretation, and personalized therapy on these diseases

Key Benefits of Report

• This study presents the analytical depiction of the Cri-du-chat syndrome treatment along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Cri-du-chat syndrome treatment market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the Cri-du-chat syndrome treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
• The report provides a detailed Cri-du-chat syndrome treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in Cri-du-chat syndrome Treatment Market Report

• Who are the leading market players active in the Cri-du-chat syndrome treatment market?
• What current trends will influence the Cri-du-chat syndrome treatment market in the next few years?
• What are the driving factors, restraints, and opportunities in the Cri-du-chat syndrome treatment market?
• What future projections would help in taking further strategic steps?
• What is Cri-du-chat syndrome treatment?
• What is Cri-du-chat syndrome treatment market prediction for the future?
• Who are the leading global players in the Cri-du-chat syndrome treatment market?
• What are the current trends and predicted trends?
• What are the key benefits of the Cri-du-chat syndrome treatment market report?

 Key Market Segments

 
Key Market Players

• Centogene N.V.
• Eurofins Scientific
• Hoffmann-La Roche Ltd
• Invitae Corporation
• Illumina Inc.
• Natera Inc.
• Progenity Inc.
• PerkinElmer Inc.
• Quest Diagnostic Incorporated
• Lifecodexx AG
• Ravgen Inc.
• Sequenom Inc.